AC IMMUNE SA SF-02 (F:IMR) — Stock Price
AC IMMUNE SA SF-02 (F:IMR) is currently trading at €1.96 EUR, up 1.66% today. Over the past 52 weeks, shares have ranged between €1.67 and €3.32. This page tracks AC IMMUNE SA SF-02's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see IMR market cap.
AC IMMUNE SA SF-02 (IMR) Stock Price Chart — Daily History & Trading Volume
The chart below tracks AC IMMUNE SA SF-02's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
AC IMMUNE SA SF-02 Income Statement — Revenue, Profit & Earnings by Year
AC IMMUNE SA SF-02's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €3.57 Million | €27.31 Million | €14.80 Million | €3.94 Million | €0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | €56.44 Million | €62.57 Million | €54.61 Million | €60.34 Million | €62.28 Million |
| SG&A | €11.65 Million | €11.43 Million | €10.58 Million | €9.58 Million | €10.88 Million |
| Total Operating Expenses | €72.44 Million | €79.69 Million | €68.42 Million | €74.78 Million | €79.01 Million |
| Operating Income | €-68.86 Million | €-52.38 Million | €-53.62 Million | €-70.85 Million | €-79.01 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €191.00K | €133.00K | €176.00K | €355.00K | €581.00K |
| Income Before Tax | €-70.45 Million | €-50.91 Million | €-54.22 Million | €-70.74 Million | €-72.99 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-70.45 Million | €-50.92 Million | €-54.23 Million | €-70.75 Million | €-73.00 Million |
AC IMMUNE SA SF-02 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes AC IMMUNE SA SF-02's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €154.25 Million | €230.91 Million | €182.81 Million | €185.94 Million | €261.44 Million |
| Total Current Assets | €96.72 Million | €171.99 Million | €125.15 Million | €128.09 Million | €202.63 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €64.62 Million | €129.21 Million | €24.55 Million | €91.00 Million | €116.00 Million |
| Net Receivables | — | €0.00 | €14.80 Million | €0.00 | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €109.37 Million | €118.64 Million | €22.17 Million | €16.95 Million | €29.46 Million |
| Total Current Liabilities | €94.69 Million | €100.84 Million | €13.58 Million | €11.48 Million | €20.03 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €44.88 Million | €112.27 Million | €160.64 Million | €168.99 Million | €231.98 Million |
| Retained Earnings | €-439.02 Million | €-368.24 Million | €-316.20 Million | €-264.01 Million | €-200.94 Million |
AC IMMUNE SA SF-02 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how AC IMMUNE SA SF-02 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-69.26 Million | €65.84 Million | €-60.41 Million | €-73.57 Million | €-65.69 Million |
| Capital Expenditures | €900.00K | €576.00K | €801.00K | €1.24 Million | €2.63 Million |
| Free Cash Flow | €-70.16 Million | €65.27 Million | €-61.21 Million | €-74.81 Million | €-68.32 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €-1.02 Million | €-1.12 Million | €43.25 Million | €-1.35 Million | €40.75 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €4.40 Million | €5.47 Million | €4.37 Million | €3.33 Million | €4.13 Million |
| Depreciation | €2.50 Million | €2.16 Million | €2.21 Million | €2.36 Million | €2.41 Million |
| Change in Cash | €-6.74 Million | €-40.57 Million | €48.49 Million | €-51.15 Million | €-78.61 Million |
AC IMMUNE SA SF-02 Earnings History — EPS Actual vs. Analyst Estimates
Track AC IMMUNE SA SF-02's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 04, 2026 | — | -0.11 | — |
| Apr 29, 2026 | — | -0.14 | — |
| Mar 12, 2026 | — | -0.17 | — |
| Nov 04, 2025 | — | -0.17 | — |
| Aug 04, 2025 | — | — | — |
| Apr 30, 2025 | — | — | — |
| Mar 12, 2025 | — | — | — |
| Nov 04, 2024 | — | — | — |